Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of Care
Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of Care
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Nothing has changed cancer therapy more in the past 5 to 10 years than the introduction of immune checkpoint inhibitors. In solid tumors, the activity of these agents is commonly linked to the presence of a hypermutated phenotype with the expression of tumor-specific neoantigens at the surface of cancer cells that can serve as targets for T cells....
Alternative Titles
Full title
Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of Care
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2466769018
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2466769018
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMe2031294
